Masked men burn a market in a Mexican city plagued by gang violence, killing 9 people

TOLUCA,Mexico--MaskedgunmensetfiretoapublicmarketinthecentralMexicancityofTolucaonMonday,killingnine MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa




comprehensive

author：fashion    Page View：9294
Novo Nordisk headquarters -- health coverage from STAT
LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines. 

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure. 

advertisement

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Gene therapies for deafness raise the question: Do deaf people want a 'cure'?
Next article： Medical leaders decry Supreme Court decision on affirmative action